Clinical Diagnosis

Current Fuchs endothelial corneal dystrophy treatments include implanted cultured human endothelial cells.

Cochair Kelly K. Nichols, OD, PhD, MPH, FAAO, highlights her passion for dry eye research and the vital collaboration between ophthalmology and optometry at EyeCon.

Early diagnosis of NMOSD is key to preventing disability, improving survival.

Researchers train deep learning model on OCT scans to ID patients eligible for GA trials.

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss nonleaking cystoid macular edema and subretinal fluid out of proportion to optic disc edema in idiopathic intracranial hypertension in the setting of optic atrophy.

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss a unique case of a 15-year-old who showed signs of meningioma with epithelial whirls and some psammoma bodies in the eye.

According to Genentech, faricimab-svoa is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness.

In this PER On Air Ophthalmology Times podcast, a team of experts provides insights into the diagnosis and management of patients with NK (including assessing their underlying cause of NK), with a look at the range of treatments available for patients with advanced stages of NK.

This PER On Air - Ophthalmology Times podcast examines the new treatment paradigm for patients with geographic atropy, following the introduction of complement-targeting therapies.

In this Ophthalmology Times EyePod podcast, Mandeep S. Singh, MD, PhD, speaks with Mark S. Humayun, MD, PhD, about the progress made by a team of USC researchers on a novel stem cell patch for treating advanced dry age-related macular degeneration.

Optimizing corneal neurotization outcomes with cryopreserved amniotic membrane.

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss how isolated empty sella is not a sign of elevated ICP

VISTA is a global randomly assigned, controlled, masked, multi-center pivotal study evaluating the efficacy, safety, and tolerability of 2 dose levels of AGTC-501 for the treatment of X-linked retinitis pigmentosa

Positive data from the GALE long-term extension study showed patients developed fewer new scotomatous points with 36 months of both continuous monthly and every-other-month treatment.

Researchers examined data of more than 200,000 people, some at an early stage of the disease and some without age-related eyesight issues

According to the company, it will finalize its Phase 3 development plans following an End-of-Phase 2 meeting with the FDA.

Low birth weight, blood transfusion, necrotising enterocolitis, bronchopulmonary dysplasia and antenatal steroid and surfactant therapies are among the factors that affect the development of ROP.

Investigators put forth a list of considerations for surgeons ahead of lens removal in pediatric patients

According to a study, the research reveals that boosting a specific protein, IRAK-M, in retinal cells could offer a new and highly effective therapy for AMD

Authors pointed out that understanding this link may aid with genetic counseling or surveillance of affected individuals, potentially contributing to improved management and outcomes.

MELT-300 is a non IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg).

Schocket has been serving as Interim chair since July, 2022, and during that time has worked to establish best practices for the department, strengthening its academic programs and improving its financial viability.

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss how modern high-resolution MRIs may miss up to a third of internuclear ophthalmoplegia (INO) lesions

Understanding how the intricate networks of blood vessels in the eye and brain are formed ultimately could inspire new treatments for conditions like diabetic retinopathy and stroke.

Ocugen is developing OCU410 as a 1-time gene therapy for the treatment of geographic atrophy. It utilizes an AAV delivery platform for the retinal delivery of the ROR Related Orphan Receptor A gene.